Events & Presentations

Investors

Events & Presentations

Upcoming Events
Date Event Details Remind Me
Mar 26, 2019 4:35 PM EDT
Oligonucleotide & Precision Therapeutics (OPT) Congress
James Hamilton, M.D., Arrowhead’s vice president of clinical development, will deliver an oral presentation titled, “siRNA Clinical Development Based on the TRiMTM Platform”
Cambridge, MA
Mar 27 - Mar 30, 2019
CSHL Meeting: RNA & Oligonucleotide Therapeutics
Dr. Hamilton will deliver an oral presentation titled, “Cardiovascular and lipid disorders - A next frontier for TRiMTM RNAi”
Cold Spring Harbor, NY
Apr 3, 2019 8:00 AM EDT
AACR Annual Meeting 2019
So Wong, Ph.D., Arrowhead’s director of oncology, will deliver a poster presentation titled, “Optimizing the potency and dosing design for ARO-HIF2: An RNAi therapeutic for clear cell renal cell carcinoma”
Apr 10, 2019
The EASL International Liver Congress 2019

Oral Presentation:
Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg <100 IU/mL threshold

  • Presentation Reference: PS-080
  • Session: Parallel session: Hepatitis B - drug development
  • Date and Time: April 12, 2019 at 5:45 p.m. CET
  • Authors: Man-Fung Yuen, et al.

Poster Presentation:
Reduction of hepatic Z-alpha1 antitrypsin by RNA interference (RNAi) prevents and reverses liver disease including hepatic mitochondrial injury in the PiZ mouse model

  • Presentation Reference: FRI-446
  • Session: Poster: Rare liver diseases (including pediatric and genetic)
  • Session Date and Time: April 12, 2019 from 9 a.m. to 5 p.m. CET
  • Authors: Christine Wooddell, et al.
Archived Events
Date Event Details
Sep 30 - Oct 3, 2018
The 14th Annual Meeting of the Oligonucleotide Therapeutics Society
Seattle, WA

October 1, 9:20 a.m. PDT – Zhen Li, Ph.D., Arrowhead’s senior vice president of chemistry and non-clinical development, will deliver an oral presentation titled, “Direct conjugation approaches in RNAi come of age – Successful delivery outside of hepatocytes”

October 1, 5:00 p.m. PDT – Rui Zhu, Ph.D., Arrowhead’s senior process chemist, will deliver a poster presentation titled, “Subcutaneous delivery of an effective RNA interference (RNAi) therapeutic candidate silencing angiopoietin-like protein 3 for treatment of hyperlipidemia”

October 3,4:00 p.m. PDT – James Hamilton M.D., MBA,Arrowhead’s vice president of clinical development, will deliver an invited, late-breaker oral presentation titled, “Clinical Development of RNAi Therapeutics for HBV and Alpha-1 Antitrypsin Deficiency”

Sep 25, 2018 12:00 PM EDT
Antivirals: Targeting HBV and Beyond
James Hamilton, M.D., Arrowhead’s vice president of clinical development, will deliver an oral presentation titled, “Using siRNA to target the HBV transcriptome”
Sep 16, 2018 12:15 PM CDT
European Respiratory Society International Congress 2018
September 16, 12:15 p.m. CEST – Erik Bush, Ph.D., Arrowhead’s director of extra-hepatic targeting, will deliver an oral presentation titled, Targeting ENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis”
Sep 7, 2018 5:45 PM EDT
18th World Gastroenterologists Summit
September 7, 09:45 a.m. NZST – Dr. Given will deliver a keynote presentation titled, “Hepatitis B in focus: New biology, new targets and real hope for finite therapy”
Sep 4, 2018
Annual B. Riley FBR Healthcare Conference
Bruce Given, M.D., Arrowhead’s chief operating officer, and Vincent Anzalone, CFA, vice president of investor relations, will participate in three panel discussions
Aug 7, 2018 4:30 PM EDT
Arrowhead Fiscal 2018 Third Quarter Results
Jun 29, 2018 3:45 PM PDT
27th Annual Alpha-1 National Education Conference
San Francisco, CA
Bruce Given, M.D., will deliver an oral presentation titled, “Development of ARO-AAT, an RNAi based therapeutic for Alpha-1 antitrypsin deficiency-related liver disease”
Jun 20, 2018 9:00 AM EDT
JMP Securities Life Science Conference
New York, NY
Bruce Given, M.D., will present a corporate overview
Jun 15, 2018 2:15 PM EDT
Global Hepatitis Summit 2018
Toronto
Christine Wooddell, Ph.D., Arrowhead’s director of liver targeting, will deliver an oral presentation titled, “Interferon-gamma pathway is activated in a chronically HBV infected chimpanzee that controls HBV following ARC-520 RNAi treatment”
Jun 8, 2018 5:30 PM +08
The Science of HBV Cure 2018
Suntec City, Singapore
Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, will deliver an oral presentation titled, “Hitting HBV everywhere; why RNAi holds so much potential as a platform therapy in CHB”